mynth is the first free M&A database dedicated to European Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.

How to use mynth for free?

Sign up for free and instantly receive 30 credits. Through our referral program, each person you invite earns you an additional 20 credits, meaning you can unlock at least 50 financial data points without spending a cent. Our search engine is built for speed and precision: filter transactions by company name, investment fund, sector, country, revenue range, enterprise value or date. A list system lets you group transactions into custom peer groups and export them directly to Excel. The credit model means you only spend on the deals you actually need : no subscription, no commitment.

mynth is a community-driven database. Every transaction is contributed by M&A and Private Equity professionals who work on the deals themselves. This means our database contains off-market financial data that you will not find in any press release, news article, or traditional data provider. Closed deals, undisclosed valuations, real EBITDA multiples : data that only exists within the deal teams. Every single financial figure submitted is reviewed and validated by our in-house analysts before being published, ensuring the data you see is accurate, structured, and reliable.

What is the best free M&A database?

mynth is the first free M&A database for European Small & Mid-Cap transactions, offering verified EV/EBITDA and EV/Revenue multiples at no cost.

How to find EV/EBITDA multiples for free?

mynth provides free access to EV/EBITDA multiples for European M&A transactions. Sign up for free and receive 30 credits to unlock individual deal financials.

What is a free alternative to Capital IQ?

mynth is a free alternative to Capital IQ for European Small & Mid-Cap M&A data, offering EBITDA multiples, revenue multiples and enterprise values without subscription fees.

← Database

M&A

ATOS MEDICAL

Acquired by

PAI PARTNERS

SWEDEN Life Sciences EV [500m EUR - 1b EUR] 06/2016

ATOS MEDICAL acquired by PAI PARTNERS

SWEDEN Life Sciences EV [500m EUR - 1b EUR] 06/2016

Target

ATOS MEDICAL

Acquirer

PAI PARTNERS

Context

PAI Partners has entered into a definitive agreement to acquire 100% of Atos Medical from EQT. This secondary LBO represents the 10th investment of the PAI Europe VI fund and marks the exit of EQT, which had overseen a period where the company doubled in size within five years. The current management team, led by CEO Claus Bjerre, remains in place to lead the next phase of the company's development under PAI's sponsorship. The strategic rationale for the acquisition is centered on the underpenetrated nature of the global laryngectomy market and the scalability of Atos Medical's direct-to-consumer model. PAI intends to leverage its healthcare sector capabilities to accelerate the company's transformational strategy, focusing on increased R&D investment and a broader global sales footprint. The deal is underpinned by the target's exceptional financial performance, including a 30% revenue growth in 2015 and industry-leading margins.

Target

Founded in 1986, Atos Medical is the global market leader in laryngectomy care, specialized in supporting patients living with a neck stoma. The company’s core business model focuses on restoring speaking ability and improving pulmonary health for patients who have undergone surgical removal of the voice box or tracheostomy procedures. Its value proposition is built on a unique direct-to-consumer (DTC) model, which accounts for approximately 50% of its laryngectomy revenues, ensuring personalized care and long-term patient engagement. Atos Medical’s strategy emphasizes clinical innovation and geographical expansion, providing high-quality medical consumables such as heat and moisture exchangers (HMEs) and voice prostheses. By diversifying into the tracheostomy segment through selective acquisitions, the company has established itself as a comprehensive Ear, Nose, and Throat (ENT) specialist. With a direct presence in 30 countries and a distribution network reaching ~90 markets, Atos Medical combines technical medical expertise with a patient-centric service layer to maintain industry-leading margins and high organic growth.

Ent. Value

Equity Value

Multiples Analysis

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with ATOS MEDICAL

Date	Acquirer	Target	Country	Sector	Deal Context
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Life Sciences	Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market. The rationale for the acquisition is highly strategic for Coloplast, as it adds a new chronic care segment to its existing portfolio. Atos Medical’s business model is a perfect fit for Coloplast’s "Chronic Care" strategy, characterized by high-recurring revenue from medical consumables and a strong direct-to-consumer orientation. The merger allows Coloplast to leverage Atos Medical’s industry-leading margins and unique patient-reach capabilities while providing Atos with Coloplast’s massive global infrastructure to further accelerate expansion in emerging and under-penetrated markets.